Three exceptional postdoctoral researchers will each receive a $300,000 grant, awarded over two years, to support their innovative biomedical research relevant to IBD.
The Rainin Foundation’s early and ongoing investments in three companies help illustrate the opportunities and challenges in this sector.
Explore highlights from our conversation with Steve Axelrod, PhD, President and CEO at G-Tech Medical, which has developed a non-invasive technology to monitor gut motility.
Explore highlights from our conversation with Julie Saiki, PhD, of Azora Therapeutics, a clinical-stage biopharmaceutical company developing an alternative to immuno-suppressive therapies.
Highlights from our conversation with Gary Mathias of Thetis Pharmaceuticals, a clinical-stage biopharmaceutical company developing alternatives to immuno-suppressive therapies.
Grantees are testing novel ideas from bright light therapy to diet and the gut-brain connection in the hopes of discovering new ways to reduce the risk of flare-ups and improve the lives of patients with IBD.
